The four key trials comparing DOACs with warfarin in AF include RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy), ROCKET AF (Rivaroxaban OD Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), and ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48). The gene discussed is F10; the disease is stroke disorder.